Closed Solicitation · DEPT OF DEFENSE
AI Summary
The U.S. Army Medical Research Acquisition Activity (USAMRAA) plans to negotiate a sole source contract with Portland State University for research on Novel Antimalarial Drug Targets. This project will support the Walter Reed Army Institute of Research's investigation into compound WR936909's Structure-Activity Relationship, requiring expertise in chemistry and testing in both the Plasmodium asexual blood-stage and liver-stage models. The performance will take place at the contractor's facility.
Place of Performance: Contractor Facility
The United States Army Medical Research Acquisition Activity (USAMRAA) intends to negotiate on a sole source basis IAW FAR 13.5 to Portland State University (PSU) 1600 SW 4th Ave. Portland, OR 97201 as the only responsible source that can provide Walter Reed Army institute of Research (WRAIR), Center for Infectious Disease Research (CIDR), Viral Diseases Branch (VDB) to support the investigation of Novel Antimalarial Drug Targets through affinity-based pulldowns. Research efforts shall require chemistry expertise in compound WR936909 Structure-Activity Relationship (SAR) in order to produce probes and activity-based protein profiling. As well collaborator must be able to first test compounds and chemical probes in the Plasmodium asexual blood-stage assay before compounds and chemical probes are moved into the Plasmodium liver-stage model.
NOVEL ANTIMALARIAL DRUG TARGETS is a federal acquisition solicitation issued by DEPT OF DEFENSE. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.